Chemotherapy-induced Thrombocytopenia: Literature Review

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2023 Jan 25

PMID 36695938

Authors

Ai Gao

Linlin Zhang

Diansheng Zhong

Affiliations

Soon will be listed here.

Abstract

Chemotherapy-induced thrombocytopenia (CIT) is a common condition that frequently results in reduced chemotherapy dosages, postponed treatment, bleeding, and unfavorable oncological outcomes. At present, there is no clear suggestions for preventing or treating CIT. Thrombopoietin (TPO) replacement therapy has been invented and used to treat CIT to promote the production of megakaryocytes and stimulate the formation of platelets. However, this treatment is limited to the risk of immunogenicity and cancer progression. Therefore, an unmet need exists for exploring alternatives to TPO to address the clinical issue of CIT. Application of appropriate therapeutic drugs may be due to understanding the potential mechanisms of CIT. Studies have shown that chemotherapy significantly affects various cells in bone marrow (BM) microenvironment, reduces their ability to support normal hematopoiesis, and may lead to BM damage, including CIT in cancer patients. This review focuses on the epidemiology and treatment of cancer patients with CIT. We also introduce some recent progress to understand the cellular and molecular mechanisms of chemotherapy inhibiting normal hematopoiesis and causing thrombocytopenia.

Citing Articles

Potential effects of liver dysfunction at the time of diagnosis in patients with acute myeloid leukemia.

Yilmaz F, Saygili D, Saglam B, Aras M, Afacan Ozturk H, Gunes A Exp Ther Med. 2025; 29(2):45.

PMID: 39817155 PMC: 11733405. DOI: 10.3892/etm.2025.12795.

Structure of blood cell-specific tubulin and demonstration of dimer spacing compaction in a single protofilament.

Montecinos F, Eren E, Watts N, Sackett D, Wingfield P J Biol Chem. 2024; 301(2):108132.

PMID: 39725029 PMC: 11791314. DOI: 10.1016/j.jbc.2024.108132.

The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.

Kos M, Tomaka P, Mertowska P, Mertowski S, Wojnicka J, Blazewicz A J Clin Med. 2024; 13(22).

PMID: 39597882 PMC: 11594473. DOI: 10.3390/jcm13226738.

Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series.

Galamaga R, Johnston S, Acosta C Br J Haematol. 2024; 206(1):272-278.

PMID: 39434457 PMC: 11739760. DOI: 10.1111/bjh.19797.

Potential Player of Platelet in the Pathogenesis of Cardiotoxicity: Molecular Insight and Future Perspective.

Amin A, Mohajerian A, Ghalehnoo S, Mohamadinia M, Ahadi S, Sohbatzadeh T Cardiovasc Toxicol. 2024; 24(12):1381-1394.

PMID: 39397196 DOI: 10.1007/s12012-024-09924-8.

References

Meng A, Wang Y, Brown S, van Zant G, Zhou D . Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms. Exp Hematol. 2003; 31(12):1348-56. DOI: 10.1016/j.exphem.2003.08.014. View

Gao A, Gong Y, Zhu C, Yang W, Li Q, Zhao M . Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. Haematologica. 2019; 104(10):1950-1961. PMC: 6886411. DOI: 10.3324/haematol.2018.214593. View

Johnstone C, Rich S . Bleeding in cancer patients and its treatment: a review. Ann Palliat Med. 2018; 7(2):265-273. DOI: 10.21037/apm.2017.11.01. View

Das B, Antoon R, Tsuchida R, Lotfi S, Morozova O, Farhat W . Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth. Neoplasia. 2008; 10(10):1105-19. PMC: 2546596. DOI: 10.1593/neo.08466. View

Al-Samkari H, Grace R, Kuter D . The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020; 11:2040620720912992. PMC: 7236573. DOI: 10.1177/2040620720912992. View

Young K . Localization of megakaryocytes in the bone marrow. Blood Cells. 1989; 15(1):15-21. View

Humbrecht C, Kientz D, Gachet C . Platelet transfusion: Current challenges. Transfus Clin Biol. 2018; 25(3):151-164. DOI: 10.1016/j.tracli.2018.06.004. View

Weycker D, Hatfield M, Grossman A, Hanau A, Lonshteyn A, Sharma A . Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019; 19(1):151. PMC: 6376753. DOI: 10.1186/s12885-019-5354-5. View

Gong Y, Zhao M, Yang W, Gao A, Yin X, Hu L . Megakaryocyte-derived excessive transforming growth factor β1 inhibits proliferation of normal hematopoietic stem cells in acute myeloid leukemia. Exp Hematol. 2018; 60:40-46.e2. DOI: 10.1016/j.exphem.2017.12.010. View

10.

Elting L, Rubenstein E, Martin C, Kurtin D, Rodriguez S, Laiho E . Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001; 19(4):1137-46. DOI: 10.1200/JCO.2001.19.4.1137. View

11.

Cheng H, Hao S, Liu Y, Pang Y, Ma S, Dong F . Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood. 2015; 126(11):1302-13. PMC: 4574014. DOI: 10.1182/blood-2015-01-623645. View

12.

Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R . Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res. 2007; 67(10):4767-73. DOI: 10.1158/0008-5472.CAN-06-4303. View

13.

Quirk S, Shure A, Agrawal D . Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res. 2015; 166(5):412-24. PMC: 4609598. DOI: 10.1016/j.trsl.2015.06.005. View

14.

Bussel J, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple J . A Review of Romiplostim Mechanism of Action and Clinical Applicability. Drug Des Devel Ther. 2021; 15:2243-2268. PMC: 8165097. DOI: 10.2147/DDDT.S299591. View

15.

Kopp H, Avecilla S, Hooper A, Shmelkov S, Ramos C, Zhang F . Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 2005; 106(2):505-13. PMC: 1895182. DOI: 10.1182/blood-2004-11-4269. View

16.

Vadhan-Raj S, Verschraegen C, Bueso-Ramos C, Broxmeyer H, Kudelka A, Freedman R . Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000; 132(5):364-8. DOI: 10.7326/0003-4819-132-5-200003070-00005. View

17.

Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella M . Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018; 132(25):2629-2638. PMC: 6337824. DOI: 10.1182/blood-2018-06-855221. View

18.

Weiss J, Goldschmidt J, Andric Z, Dragnev K, Gwaltney C, Skaltsa K . Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clin Lung Cancer. 2021; 22(5):449-460. DOI: 10.1016/j.cllc.2021.03.010. View

19.

Al-Samkari H, Parnes A, Goodarzi K, Weitzman J, Connors J, Kuter D . A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2020; 106(4):1148-1157. PMC: 8018116. DOI: 10.3324/haematol.2020.251900. View

20.

Bussel J, Kulasekararaj A, Cooper N, Verma A, Steidl U, Semple J . Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol. 2019; 56(4):262-278. DOI: 10.1053/j.seminhematol.2019.09.001. View